What kind of targeted drug is larotinib/larlotinib?

Larotrectinib/Larotrectinib is a selective TRK inhibitor specifically targeted at patients with solid tumors with NTRK gene fusion mutations. NTRK fusion mutations lead to abnormal activation of TRK protein, thereby triggering the continued growth and spread of tumor cells. Larotrectinib inhibits tumor growth by highly selectively inhibiting the activity of the TRK family (TRKA, TRKB, TRKC) and blocking abnormal signaling pathways. Its biggest advantage is that it is not limited to cancer types, that is, no matter which organ the tumor originates from, as long as there is NTRK gene fusion, it may benefit. Therefore, larotrectinib is considered an important representative of broad-spectrum anti-cancer targeted drugs and has shown significant efficacy in various solid tumors such as lung cancer, thyroid cancer, sarcoma, and colorectal cancer.